Investigational drug · Phase 3
GC5107
Also called: GCC 10% IGIV
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Primary Immune Deficiency.
Phase 3Last checked: Nov 19, 2026Latest source record: Jul 25, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "GC5107"
First trial start
2020
Dec 21, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GC5107", any sponsor or status.
Conditions studied
As listed on its trial records.
- Primary Immune Deficiency
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "GC5107" as an intervention, largest first.
- Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral ImmunodeficiencyPivotal-lookingCompleted
Green Cross CorporationIndustry
NCT02783482 · 49 participants · Start Oct 2016 · Primary completion Jul 2019
Drug: GC5107 · For: Immunologic Deficiency Syndromes
Sites: Centennial, Colorado; North Palm Beach, Florida; Plymouth, Minnesota · 20 sites in all
- Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral ImmunodeficiencyPivotal-lookingActive, not recruiting
GC Biopharma CorpIndustry
NCT04565015 · 24 participants (planned) · Start Dec 21, 2020 · Primary completion May 2026
Drug: GC5107 · For: Primary Immune Deficiency
Sites: Aurora, Colorado; Centennial, Colorado; Dallas, Texas · 8 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Cation exchange chromatography removes FXIa from a 10% intravenous immunoglobulin preparation.
Kang GB, Huber A, Lee J, et al. · Front Cardiovasc Med 2023
- Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies.
Perez EE, Hébert J, Ellis AK, et al. · Front Immunol 2021
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.